Latest news
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/unite4tb-4.png)
![](https://amr-accelerator.eu/wp-content/uploads/2022/02/primavera-1.png)
![](https://amr-accelerator.eu/wp-content/uploads/2021/10/unite4tb-4.png)
![](https://amr-accelerator.eu/wp-content/uploads/2024/04/Asset-1.png)
![](https://amr-accelerator.eu/wp-content/uploads/2020/09/Circle_ABDirect.png)
![](https://amr-accelerator.eu/wp-content/uploads/2022/02/primavera-1.png)
Interviews
![](https://amr-accelerator.eu/wp-content/uploads/2023/11/Respiris_interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2023/01/IHI_Interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2022/06/PRIMAVERA_Interview.jpg)
![](https://amr-accelerator.eu/wp-content/uploads/2021/11/IMI_ERA4TB.jpg)
Newsletters
From the partners
![](https://amr-accelerator.eu/wp-content/uploads/2022/01/Partner_PrIMAVeRa_0000_ares-495x400.jpg)
26/07/22 – OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
![](https://amr-accelerator.eu/wp-content/uploads/2022/07/Evotec-495x400.png)
06/07/22 – Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
![](https://amr-accelerator.eu/wp-content/uploads/2022/04/NICE-495x400.png)
12/04/22 – NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance
![](https://amr-accelerator.eu/wp-content/uploads/2022/03/Uni-Dundee-495x400.png)
![](https://amr-accelerator.eu/wp-content/uploads/2019/04/LogoSantPau-495x400.png)
![](https://amr-accelerator.eu/wp-content/uploads/2023/07/Uni-Oxford-UCL-495x400.png)
ERA4TB Newsletter – September 2022
UNITE4TB Newsletter – September 2022
RespiriNTM & -TB Newsletter – May 2022
AMR ACCELERATOR NEWSLETTER – MAY 2022
ERA4TB Newsletter – February 2022
AMR Accelerator Newsletter – November 2021